araag2/HINT huggingface dataset:
Clinical trial NCT01137682 (phase 3, status: completed)
Conditions: acromegaly
ICD codes: E22.0
Drugs: pasireotide, octreotide lar 30mg, lanreotide atg 120mg
SMILES: NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1, [H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O, [H]N([H])CCCCC1N([H])C(=O)C(CC2=CN([H])C3=CC=CC=C23)N([H])C(=O)C(CC2=CC=C(O)C=C2)N([H])C(=O)C(CSSCC(N([H])C(=O)C(N([H])C1=O)C(C)C)C(=O)N([H])C(C(C)O)C(=O)N([H])[H])N([H])C(=O)C(CC1=CC2=CC=CC=C2C=C1)N([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with written informed consent prior to any study related activity

          2. Patients who had inadequately controlled acromegaly as defined by a mean GH
             concentration of a 5-point profile over a 2-hour period > 2.5 µg/L and sex- and
             age-adjusted IGF-1 > 1.3 x upper limit of normal (ULN)

          3. Patients who had been treated with maximum indicated doses of octreotide LAR or
             lanreotide ATG for at least 6 months prior to visit 1 (screening). The maximum
             indicated dose for octreotide LAR was 30mg and for lanreotide ATG iwas120 mg

          4. Patients who had a diagnosis of pituitary micro- or macro adenoma. Patients could have
             been previously submitted to surgery

          5. Patients who completed the 24-week treatment period in core according to the
             requirements of the core study protocol or corresponding amendments could enter
             extension

        Exclusion Criteria:

          1. Patients who had received pasireotide (SOM 230) prior to enrolment

          2. Concomitant treatment with Growth Hormone Receptor (GHR)-antagonist or dopamine
             agonists unless concomitant treatment was discontinued 8 weeks prior to visit 1
             (screening)(8 weeks wash out period). Such patients must have been treated with
             octreotide LAR 30 mg or lanreotide ATG 120 mg monotherapy continuously for a minimum
             of 6 months prior to starting combination therapy and they should have been
             inadequately controlled on monotherapy.

          3. Patients who had compression of the optic chiasm causing acute clinically significant
             visual field defects

          4. Patients who required a surgical intervention for relief of any sign or symptom
             associated with tumor compression

          5. Patients who had received pituitary irradiation within 10 years prior to visit 1
             (screening).

          6. Patients who had undergone major surgery/surgical therapy for any cause within 4 weeks
             prior to visit 1 (screening).

          7. Patients who were hypothyroid and not adequately treated with a stable dose of thyroid
             hormone replacement therapy
Clinical trial NCT01576419 (phase 3, status: completed)
Conditions: osteoarthritis of the knee
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: pg201 tablet, celebrex capsule
SMILES: CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          1. Patients ≥40 and ≤ 80years of age.

          2. Patients who meet the American College of Rheumatology clinical plus radiographic
             classification criteria for idiopathic osteoarthritis of the knee, which are defined
             as follow:

             a patient who had knee pain and radiographically diagnosed osteophytes and met at
             least one of the followings.

               -  Age> 50 years.

               -  Morning stiffness for less than 30 minutes.

               -  Crepitus during movement of the weight-bearing knee.

          3. Patients with symptomatic primary osteoarthritis of the knee at least in the last 3
             months prior to screening.

          4. Patients who received Nonsteroidal antiinflammatory drugs (NSAIDs)/Cyclooxygenase-2
             inhibitor for the treatment of arthritis of the knee for at least 5 days a week during
             4 weeks prior to screening.

          5. Patients who had a score of 100mm pain VAS ≤80 mm at screening.

          6. Patients who had a score of 100mm pain VAS ≥50 mm at baseline.

          7. Patients should be able and willing to provide the written informed consent.

        Exclusion Criteria:

          1. Patients with a history of surgery or arthroscopy of the study joint within the
             previous 6 months.

          2. Patients with trauma of study joint within the previous 12 months.

          3. Patients with symptomatic hip osteoarthritis, other condition that would interfere
             with study assessments.

          4. Patients with any other type of arthritis, active malignancies or any active GI,
             cardiovascular, renal, hepatic, neurologic, or psychiatric disease.

          5. Patients with a known hypersensitivity or intolerance to Nonsteroidal antiinflammatory
             drugs (NSAIDs), aspirin or Cyclooxygenase-2 inhibitor.

          6. Patients with uncontrollable hypertension.

          7. Patients with any of creatinine, bilirubin, Alanine aminotransferase or Aspartate
             aminotransferase > 1.5 times the Upper Lange of normal at screening.

          8. Patients with a history of drug or alcohol abuse.
Clinical trial NCT01031628 (phase 3, status: terminated)
Conditions: gastrointestinal stromal tumors
ICD codes: C49.A0, C49.A1, C49.A2, C49.A5, C49.A3, C49.A4, C49.A9
Drugs: imatinib mesylate, imatinib mesylate, imatinib mesylate
SMILES: CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Reason stopped: 
    lack of feasibility secondary to slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Unresectable and/or metastatic GIST

          -  Currently receiving imatinib 400 mg per day for a minimum of 4 weeks prior to
             registration, and for no more than 6 months prior to registration. This must be the
             first time that the patient has been treated for metastatic and/or unresectable GIST

          -  For patients who received imatinib following surgery at the time of an initial
             diagnosis of GIST, there must be a 6 month interval between completion of imatinib and
             the diagnosis of metastatic GIST

          -  Good physical functioning (ECOG Performance Status of 0 or 1)

          -  Generally, good function of organ such as liver and kidneys

        Exclusion Criteria:

          -  Disease progression during adjuvant therapy with imatinib (adjuvant treatment is
             treatment that is given after surgery for GIST)

          -  Known intolerance of imatinib at a dose of 400 mg/day or higher

          -  Prior systemic therapy for advanced GIST with imatinib or those who have been on
             imatinib for longer than 6 months for unresectable and/or metastatic disease

          -  Major surgery within 2 weeks prior to Day 1 of study or who have not yet recovered
             from prior surgery

          -  Use of coumadin derivatives (i.e. warfarin, acenocoumarol, phenprocoumon)

          -  Patients who have received wide field radiotherapy ≤ 4 weeks or limited field
             radiation for palliation < 2 weeks or who have not recovered from side effects of this
             therapy
Clinical trial NCT00703118 (phase 3, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: telaprevir, peg-ifn-alfa-2a, ribavirin, placebo
SMILES: [H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient must have chronic hepatitis C infection (genotype 1) with HCV RNA level >=
             1000 IU/mL

          -  Patient must have failed at least 1 prior course of Peg-IFN/RBV therapy (standard
             treatment)

          -  Patient must be willing to use 2 effective methods of birth control for up to 7 months
             after last dose of study medication

        Exclusion Criteria:

          -  Patient is a previous non-responder that is classified as a viral breakthrough case

          -  Patient is infected with Hepatitis C virus, genotype 1, exhibiting more than one
             subtype

          -  Patient has Hepatitis C virus, genotype 1, and exhibits co-infection with any other
             genotype

          -  Evidence of decompensated liver disease

          -  Patient has condition that requires use of systemic corticosteroids
Clinical trial NCT01128153 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: saxagliptin, placebo
SMILES: N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Written Informed Consent

          -  Males or females with type 2 diabetes with inadequate glycaemic control (HbA1c > or =
             7% and < or = 10%) despite being on combination of metformin and sulfonylurea for at
             least 8 weeks prior to Visit 1

          -  BMI < or = 40 kg/m2

        Exclusion Criteria:

          -  Symptoms of poorly controlled diabetes including but not limited to marked polyuria
             and marked polydipsia with > 10% weight loss in 3 months prior to entry, or other
             signs and symptoms

          -  History of diabetic ketoacidosis or hyperosmolar non-ketotic coma

          -  Current or prior use within 3 months of Visit 1 of insulin, DDP4 inhibitor, GLP-1
             analogues, and/or other oral anti-diabetic agents (other than metformin or
             sulfonylurea)

          -  Treatment with CYP3A4 inducers and/or potent CYP3A4/5 inhibitor

          -  Estimated CrCl < 60 ml/min at Visit 2

          -  CHF (NYHA class III or IV) and/or LVEF <40%

          -  Active liver disease and/or significant abnormal liver function defined as AST and/or
             ALT > 3 x ULN and/or bilirubin > 2.0 mg/dL at Visit 2.

          -  Creatine kinase > or = 10 x ULN at Visit 2
Clinical trial NCT00578929 (phase 3, status: completed)
Conditions: seasonal allergic rhinitis
ICD codes: J30.2
Drugs: olopatadine hydrochloride nasal spray 0.6%, vehicle
SMILES: CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female; minimum of 6 years of age and less than 12 years

          -  2 year history of seasonal allergic rhinitis

        Exclusion Criteria:

          -  Concurrent disease that might interfere with the investigation or evaluation of te
             study medication

          -  Confirmed diagnosis of chronic rhinosinusitis within the last year

          -  Asthma, with the exception of mild intermittent asthma

          -  Anatomical nasal deformity

          -  Nasal obstruction

          -  Known non-responder to antihistamines for symptoms of Seasonal Allergic Rhinitis (SAR)

          -  Chronic or intermittent use of of inhaled, oral, intramuscular intravenous
             corticosteroids ot topical steroids

          -  Ocular disorder other that allergic conjunctivitis
Clinical trial NCT01084005 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: linagliptin, placebo
SMILES: [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          1. Type 2 diabetes mellitus

          2. HbA1c >= 7.0%

          3. Age >= 70 years

          4. Signed and dated written informed consent

        Exclusion criteria:

          1. Myocardial infarction, stroke or TIA within 3 months prior to informed consent

          2. Impaired hepatic function

          3. Treatment with glitazones, GLP-1 analogues, DPP-4 inhibitors or rapid acting or
             pre-mixed insulins

          4. Treatment with anti-obesity drugs
Clinical trial NCT00199420 (phase 3, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: istradefylline (kw-6002)
SMILES: [H]\C(=C(\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC
Eligibility criteria:

        Inclusion Criteria:

          1. UK Parkinson's Disease Society (UKPDS) brain bank criteria (Step 1 and 2) for PD.

          2. PD stages 2-4 in the OFF state for Modified Hoehn and Yahr Scale.

          3. On levodopa/carbidopa for at least one year, stable dose in past 4 weeks.

          4. Currently take at least three doses of levodopa/carbidopa per day.

          5. Predictable end of dose wearing off.

          6. Able to satisfactorily complete Hauser version of a Parkinson's diary.

          7. Have an average of 180 minutes of OFF time on two 24 hour diaries.

          8. Be at least 30 years of age.

        Exclusion Criteria:

          1. Neurosurgical treatment for PD.

          2. History of psychosis.

          3. Diagnosis of atypical parkinsonism, secondary parkinsonism variant or Parkinson's plus
             syndromes.

          4. Diagnosis of cancer within 5 years.

          5. Mini-mental status examination score of 25 or less.

          6. History of seizures or neurologic malignant_syndrome.
Clinical trial NCT01479530 (phase 3, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: placebo, azilect®
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, C#CCN[C@@H]1CCC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with idiopathic PD.

          -  Patients with motor fluctuations averaging at least 1 hour daily in the "OFF" state
             during the waking hours.

          -  Patients with a Modified Hoehn and Yahr stage ≤3 in the "ON" state.

          -  Patients taking optimised levodopa or dopa decarboxylase inhibitor (DDI) therapy; they
             must be stable for at least 14 days prior to baseline.

          -  Patients receiving at least 3 daily doses of levodopa and not more than 8 daily doses
             of levodopa.

          -  Patients who have demonstrated the ability to keep accurate "24-hour" diaries prior to
             randomisation.

        Exclusion Criteria:

          -  Patients with a clinically significant or unstable medical or surgical condition that
             would preclude his/her safe and complete study participation.

          -  Patients with a clinically significant or unstable vascular disease.

          -  Patients who have undergone a neurosurgical intervention of PD.

          -  Patients with severe disabling dyskinesias.

          -  Patients with a clinically significant psychiatric illness, including a major
             depression, which compromises their ability to provide consent or participate fully in
             the study.

          -  Patients with a Mini Mental State Examination (MMSE) score ≤24.

          -  Patients with a diagnosis of melanoma or a history of melanoma, or a suspicious
             lesion.

        Other inclusion and exclusion criteria may apply.
Clinical trial NCT00300729 (phase 3, status: unknown status)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: celecoxib, placebo
SMILES: COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).

          -  Age at least 18 years. No upper age limit.

          -  Disease stage IIIB or IV.

          -  Performance status (WHO) 0-2

          -  Treatment with curative intent is not possible

          -  No prior chemotherapy for the present disease

          -  Planned treatment is palliative chemotherapy

          -  WBC count at least 3.0, platelet count at least 100

          -  Bilirubin < 1.5 * upper reference limit (URL), ASAT and ALAT < 3 * URL (<5 in case of
             liver metastases)

          -  Calculated creatinine clearance at least 40 mg/ml

          -  Informed oral and written consent

        Exclusion criteria:

          -  Regular use of NSAID (except ASA at a dose of 50-100 mg daily)

          -  Active duodenal ulcer, ongoing gastrointestinal bleeding or inflammatory bowel disease

          -  Serious heart failure or serious liver disease

          -  Hypersensitivity so sulfonamides

          -  Pregnancy

          -  Lactation
Clinical trial NCT01462812 (phase 3, status: completed)
Conditions: migraine headache
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: sumatriptan, placebo
SMILES: CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women, between the ages of 18 to 65 years

          -  Diagnosis of migraine, with or without aura

          -  Experiences between 1 and 8 migraine attacks per month for the past 12 months

        Exclusion Criteria:

          -  Inability to distinguish other headaches from migraine

          -  Experiences headache of any kind at a frequency greater than or equal to 15 days per
             month

          -  History of resistance to sumatriptan, or non-response to 2 or more other triptans,
             defined as subjects who have not responded to an adequate dose and duration of
             treatment

          -  Current use of medication for migraine prophylaxis that has not been stable (no dose
             adjustment) for 30 days prior to screening

          -  Chronic opioid therapy (>3 consecutive days in the 30 days prior to screening)
Clinical trial NCT00384033 (phase 3, status: completed)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: desvenlafaxine succinate sustained-release (dvs sr), desvenlafaxine succinate sustained-release (dvs sr), placebo, duloxetine 60 mg/day
SMILES: CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1, CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1
Eligibility criteria:

        Inclusion Criteria:

          -  A primary diagnosis of Major Depressive Disorder, single or recurrent episode, without
             psychotic features.

          -  Depressive symptoms for at least 30 days before the screening visit.

          -  Outpatient men and women at least 18 years of age.

        Exclusion Criteria:

          -  Significant risk of suicide based on clinical judgment, including common suicidal
             thoughts and suicide having been considered as a possible solution even without
             specific plans or intent.

          -  Any unstable hepatic, renal, pulmonary, cardiovascular (including uncontrolled
             hypertension), ophthalmologic, neurologic, or any other medical condition that might
             confound the study or put the subject at greater risk during study participation.

          -  Current (within 12 months before baseline) psychoactive substance abuse or dependence
             (including alcohol), manic episode, posttraumatic stress disorder,
             obsessive-compulsive disorder, or a lifetime diagnosis of bipolar or psychotic
             disorder; b) current (within 12 months before baseline) generalized anxiety disorder,
             panic disorder, or social anxiety disorder; c) presence (within 12 months before
             baseline) of a clinically important personality disorder as assessed during the
             psychiatric assessments.
Clinical trial NCT00354302 (phase 3, status: completed)
Conditions: breast cancer, osteoporosis
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: alendronate sodium, calcium gluconate, risedronate sodium
SMILES: NCCCC(O)(P(O)(O)=O)P(O)(O)=O, [Ca], OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Enrolled in and meets eligibility requirements for protocol CAN-NCIC-MA27

          -  Acceptable quality dual-energy x-ray absorptiometry (DEXA) of the L1-L4
             postero-anterior spine and hip within 12 weeks prior to randomization on protocol
             CAN-NCIC-MA27

          -  Hormone receptor status:

               -  Estrogen receptor- and/or progesterone receptor-positive tumor

        PATIENT CHARACTERISTICS:

          -  Female

          -  Postmenopausal

          -  No malabsorption syndrome

          -  No known cholecalciferol (vitamin D) deficiency, active hyper- or hypoparathyroidism,
             or Paget's disease

          -  No uncontrolled thyroid disease, Cushing's disease, or other pituitary disease

          -  No other bone disease (including osteomalacia or osteogenesis imperfecta)

        PRIOR CONCURRENT THERAPY:

          -  More than 6 months since prior drugs (investigational or not), including
             bisphosphonates, for the prevention of osteoporosis (stratum I)

          -  More than 12 months since prior and no concurrent anticonvulsants

          -  More than 6 months since prior and no concurrent corticosteroids at doses > 5 mg/day
             of prednisone (or equivalent) for > 2 weeks

          -  More than 12 months since prior and no concurrent anabolic steroids

          -  No prior bisphosphonates (stratum II)

          -  No concurrent sodium fluoride at daily doses ≥ 5 mg/day

          -  No long-term (i.e., > 6 months) use of coumarins

          -  No concurrent drugs (investigational or not), including bisphosphonates, for the
             prevention of osteoporosis (for patients with no osteopenia or osteoporosis [stratum
             I])